Finally, future studies are needed to elucidate the precise downstream mechanisms responsible for how enhanced Orai1-mediated SOCE potentiates the dystrophic phenotype, as well as to determine if therapeutic strategies designed to target these mechanisms can be effectively translated to the treatment of children with DMD. This evidence concerns the gene ORAI1 and Duchenne muscular dystrophy.